2. Search Result
Search Result
Results for "

pS6/mTORC1

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-124798
    Rheb inhibitor NR1
    3 Publications Verification

    		 mTOR Neurological Disease Inflammation/Immunology Cancer
    Rheb inhibitor NR1 is a Rheb inhibitor with an IC50 of 2.1 µM in the Rheb-IVK assay. Rheb inhibitor NR1 can directly bind Rheb in the switch II domain and selectively inhibit the activation of mechanistic target of rapamycin complex 1 (mTORC1). Rheb inhibitor NR1 inhibits the phosphorylation of mTORC1 driven T389pS6K1 and increases the phosphorylation of S473pAKT in a dose-dependent manner. Rheb inhibitor NR1 does not influence mTORC2 activity [1].
    (Rheb-IVK: Rheb-dependent mTORC1 kinase activity)
    Rheb inhibitor NR1
  • HY-132168
    RMC-5552
    5 Publications Verification

    		 mTOR Cancer
    RMC-5552 is a potent and selective mTORC1 inhibitor. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and p4EBP1 with IC50s of 0.14 nM and 0.48 nM, respectively. RMC-5552 shows much lower pAKT inhibition (IC50 of 19 nM), resulting in mTORC1/mTORC2 selectivity approaching 40-fold. RMC-5552 has anti-cancer activity [1].
    RMC-5552
  • HY-P11162
    FGF7p

    		FGFR Akt ERK mTOR Apoptosis Inflammation/Immunology
    FGF7p is a small molecule peptide and a potential bladder protector. FGF7p can activate downstream signaling pathways of FGFR2 in the urinary tract epithelium (pFRS2α, pAKT and pERK). FGF7p alleviates cyclophosphamide induced apoptosis and tissue damage in urinary tract epithelial cells by activating AKT and its downstream anti apoptotic targets (pBAD, pS6/mTORC1). FGF7p is commonly used in the study of inflammatory conditions [1].
    FGF7p
  • HY-170670
    DQ661

    		Autophagy mTOR Cancer
    DQ661 is a potent PPT1 inhibitor. DQ661 is a dimeric quinacrine autophagy inhibitor. DQ661 inhibits mTORC1 activity. DQ661 decreases the protein expression of pS6K T389, pS6 S240-244. DQ661 shows anticancer activity [1] .
    DQ661
  • HY-145931
    CC214-2

    		mTOR Autophagy Cancer
    CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo [1] .
    CC214-2
  • HY-111370
    mTOR inhibitor-2

    		mTOR Cancer
    mTOR inhibitor-2 is a highlt potent, selective and oral mTOR inhibitor with an IC50 of 7 nM. mTOR inhibitor-2 inhibits cellular phosphorylation of mTORC1 (pS6 and p4E-BP1) and mTORC2 (pAKT (S473)) substrates [1].
    mTOR inhibitor-2
  • HY-176948
    M-1111

    		mTOR Cancer
    M-1111 is a Rapa-Link inhibitor. M-1111 is covalently linked by Rapamycin (HY-10219) and an inhibitor of the active site mTOR. M-1111 has strong inhibitory activity on the mTORC1 signaling pathway (pS6 and p4E-BP1). M-1111 has nanomolar-level inhibitory activity against various cancer cells. M-1111 completely inhibits p4E-BP1 without inhibiting pAkt S473. M-1111 can be used for research on liver cancer, kidney cancer, and colorectal cancer [1].
    M-1111

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: